by CCHR—THE WEEK posted a pretty good article called “ADHD’s Rapid Rise: 5 Theories” — pretty good because though several of their theories may play some part in why so many kids are diagnosed ADHD, they never quite nail the answer. So we did. Adding to their 5 points of various theories, we (CCHR) present you with point number 6: The actual answer.
The American Psychiatric Association, in its 240 page guide to its May annual meeting, “forgot” to mention the conflicts of interest of its own president Alan Schatzberg, MD. It had to print them on the newsletter circulated the third day of the meeting. Nor were names even alphabetized for easy information retrieval. (Schatzberg is financially linked to Eli Lilly, GSK, Merck, Pfizer, Forest, Takeda, Sanofi-Aventis and eight other companies.)
More and more people, especially young adults, are being diagnosed with some sort of mental disorder. From depression and anxiety, to Attention Deficit Disorder and bipolar disorder, mental disorder diagnoses are convenient. They sum up all of our problems on a prescription bottle filled with pills that will fix everything.
Pharmaceutical companies obviously want to sell their drugs, but the selling involves deceiving the consumer. They have to sell the illness first. They present advertisements that say, “Do you have symptoms A and B? Well, this is what’s wrong with you.” It offers consumers a solution to their everyday problems. But let’s face it; when it comes to the symptoms presented by the commercials you see while watching TV, we probably all feel them at some point.
The Big News in Pharma-land is that the DOJ is going after a former GSK lawyer/Exec for a myriad of crimes which could lead to a Fashionable Federal Prison Jump Suit & a very long stay at a Martha Steward Foo Foo Club Fed. The question still remains if this scum bag exec does go to trial and is convicted (or sings like a Canary); what effect this might have on the World Wide Pharmaceutical Drug Cartel Criminal business as usual model?
Johnson & Johnson (JNJ) said it’s in discussions with the government to resolve a long-running investigation of whether it improperly marketed the antipsychotic Risperdal. In 2004, the Office of the Inspector General of the U.S. Office of Personnel Management issued a subpoena seeking documents regarding sales and marketing of Risperdal, as well as payments to physicians and clinical trials for the drug, from 1997 to 2002. The U.S. Attorney’s Office in Philadelphia sent an additional subpoena in 2005, seeking information about Risperdal marketing and adverse reactions associated with the drug. Grand jury subpoenas have been issued seeking testimony from various witnesses.